Shots: The first patient has been dosed in a P-II study evaluating the safety & preliminary efficacy of onvansertib + Irinotecan and 5-FU in ~40 patients as a 2L treatment for metastatic PDAC who have failed 1L gemcitabine-based therapy across 6 sites in the US The 1EPs of the study is ORR and 2EPs include […]Read More
In an interview with PharmaShots, Mark Erlander, CEO of Cardiff Oncology shared his views on the data presented at the ASCO-GI Conference, P-Ib results of Onvansertib, what these results meant for the patients with this aggressive type of mCRC, and the company’s other ongoing programs for Onvansertib, including metastatic castration-resistant prostate cancer and AML Shots: […]Read More
Shots: The P-Ib/II study involves assessing of Onvansertib + Folfiri and bevacizumab in 44 patients with 2L treatment of KRAS-mutated mCRC. The company also provided an additional data update from its mCRC clinical program and initial findings from its EAP Out of the 12 P-1b patients, 42% achieved PR & 67% have shown a durable […]Read More
Copyright ©2021 PharmaShots | Powered by Octavus Consulting
